We offer planning, guidance, and development of TKa testing in pharmaceutical/biotech studies and clinical trials in four different agreement types. We would be happy to help you find the solution that best fits your needs.
Technology Evaluation Service Agreement (TESA)
A TESA is for pharmaceutical/biotech companies conducting studies in the early drug development phases, wishing to quickly evaluate our blood-based biomarker assay (DiviTum® TKa) to measure cell proliferation.
Master Service Agreement (MSA)
The MSA enables a smooth, efficient execution of multiple projects/services which accelerates the generation of predictive TKa data that can be included in pivotal studies.
CDx/Research Collaboration (CDxRC)
The CDxRC focuses on a more formal development collaboration with a pharmaceutical/biotech company where we customize our TKa assay to monitor Pharma’s specific drug.
CDx Product Agreement (CPA)
The CPA is used for the collaborative development, registration, and commercialization of a companion diagnostic assay (CDx) using the 510(k) cleared DiviTum® TKa assay.